The purpose of the study is to evaluate safety and feasibility of neoadjuvant nivolumab plus
ipilimumab prior to standard therapy (surgery, chemotherapy or radiation therapy) in patients
with Neurofibromatosis Type 1 (NF1) and newly diagnosed pre-malignant and malignant
peripheral nerve sheath tumors (MPNST) for whom surgery for resection of tumor is indicated.
Nerve Sheath Tumors
Clinical Study Identifier
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.